Literature DB >> 16149157

Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha.

Kazutaka Kurokohchi1, Kouichi Takaguchi, Keiji Kita, Tsutomu Masaki, Shigeki Kuriyama.   

Abstract

We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha). In the present case, the patient had massive and advanced HCC with a diameter of over 8 cm located in segment 7 (S7) of the liver. Furthermore, the tumor invaded into the major branch of the portal vein (Vp3). After TACE, combined administration of 5-FU and PEG-IFN-alpha was performed for 5 mo. HCC was totally eradicated and the serum levels of tumor markers were markedly decreased by the treatment. Although it has been reported that the combined use of conventional IFN-alpha and 5-FU showed striking effects on HCC in some cases, this case may suggest the more promising effect of PEG-IFN-alpha with a long-lasting effect, in the combined use with 5-FU for the treatment of massive advanced HCC.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16149157      PMCID： PMC4622820          DOI： 10.3748/wjg.v11.i34.5401

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  7 in total

1.  Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.

Authors:  Masato Sakon; Hiroaki Nagano; Keizo Dono; Shoji Nakamori; Koji Umeshita; Akira Yamada; Sumio Kawata; Yasuharu Imai; Shohei Iijima; Morito Monden
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

2.  Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma.

Authors:  Kazutaka Kurokohchi; Seishiro Watanabe; Tsutomu Masaki; Naoki Hosomi; Yoshiaki Miyauchi; Takashi Himoto; Yasuhiko Kimura; Seiji Nakai; Akihiro Deguchi; Hirohito Yoneyama; Shuhei Yoshida; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

3.  Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis.

Authors:  Y H Chung; I H Song; B C Song; G C Lee; M S Koh; H K Yoon; Y S Lee; K B Sung; D J Suh
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

4.  Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis.

Authors:  Shuichi Kaneko; Takeshi Urabe; Kenichi Kobayashi
Journal:  Oncology       Date:  2002       Impact factor: 2.935

5.  Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocelluar carcinoma.

Authors:  K Kurokohchi; S Watanabe; T Masaki; N Hosomi; T Funaki; K Arima; S Yoshida; Y Miyauchi; S Kuriyama
Journal:  Int J Oncol       Date:  2002-10       Impact factor: 5.650

6.  Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat.

Authors:  Kazutataka Kurokohchi; Seishiro Watanabe; Tsutomu Masaki; Naoki Hosomi; Toshiharu Funaki; Keiji Arima; Shuhei Yoshida; Seiji Nakai; Masayuki Murota; Yoshiaki Miyauchi; Shigeki Kuriyama
Journal:  Int J Oncol       Date:  2002-09       Impact factor: 5.650

7.  Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.

Authors:  Yehuda Z Patt; Manal M Hassan; Richard D Lozano; Thomas D Brown; J Nicolas Vauthey; Steven A Curley; Lee M Ellis
Journal:  J Clin Oncol       Date:  2003-02-01       Impact factor: 44.544
  7 in total
  6 in total

1.  Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin.

Authors:  Michael D Thompson; Mohd Jamal Dar; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2010-10-29       Impact factor: 25.083

2.  Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/β-catenin pathway.

Authors:  Ming-Hai Wang; Shi-Yong Qin; Shu-Guang Zhang; Guang-Xin Li; Zhen-Hai Yu; Kun Wang; Bin Wang; Mu-Jian Teng; Zhi-Hai Peng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Hepatitis C virus core protein and cellular protein HAX-1 promote 5-fluorouracil-mediated hepatocyte growth inhibition.

Authors:  Arup Banerjee; Kousuke Saito; Keith Meyer; Sutapa Banerjee; Malika Ait-Goughoulte; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

4.  Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodol-targetting intervention radiology.

Authors:  Kazutaka Kurokohchi; Akihiro Deguchi; Tsutomu Masaki; Takashi Himoto; Hirohito Yoneyama; Mitsuyoshi Kobayashi; Tsuyoshi Maeta; Takaaki Kiuchi; Fumikazu Kohi; Hisaaki Miyoshi; Tomohiko Taminato; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

5.  Long-term pegylated interferon-alpha and its potential in the treatment of melanoma.

Authors:  Reinhard Dummer; Joanna Mangana
Journal:  Biologics       Date:  2009-07-13

6.  A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells.

Authors:  Zhongyi Cong; Min Wan; Xiuli Wu; Li Wang; Xiaoping Hu; Fenglei Yang; Musheng Bao; Xuesong Zhang; Jianzhu Chen; Liying Wang; Yongli Yu
Journal:  FEMS Immunol Med Microbiol       Date:  2007-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.